ZoeNCure Therapeutics Raises INR 20 Crore and Licenses Antibody Platform for Liver Cancer ADCs
ZoeNCure Therapeutics, an Indian oncology biotech firm, secured INR 20 Crore in seed funding led by the Tyagi Family to advance its antibody-drug conjugate (ADC) program targeting liver and gastrointestinal cancers. The company also licensed novel antibody technology from Styx Biotechnologies to develop dual-payload ADCs for hepatocellular carcinoma. These developments aim to support preclinical studies, regulatory submissions, and early-stage clinical trials to address unmet needs in liver cancer treatment in India.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 39/100.
Outlets measured: thetribune, thetribune. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetribune broke this story on 3 Sept, 11:49 am. Other outlets followed.